Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.
Identifieur interne : 001010 ( Ncbi/Checkpoint ); précédent : 001009; suivant : 001011Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.
Auteurs : Tania Ivens [Belgique] ; Christel Van Den Eynde ; Koen Van Acker ; Erik Nijs ; Géry Dams ; Eva Bettens ; Asa Ohagen ; Rudi Pauwels ; Kurt HertogsSource :
- Journal of virological methods [ 0166-0934 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
- analyse : Antiviraux.
- métabolisme : Antiviraux.
- pharmacologie : Antiviraux.
- physiologie : Virus du SRAS.
- Antiviraux, Lignée cellulaire, Protéines à fluorescence verte, Réplication virale, Virus du SRAS, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- MESH :
- chemical , analysis : Antiviral Agents.
- chemical , chemistry : Antiviral Agents.
- chemical , metabolism : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- drug effects : SARS Virus, Virus Replication.
- physiology : SARS Virus.
- Cell Line, Drug Evaluation, Preclinical, Green Fluorescent Proteins.
Abstract
The severity and global spread of the 2003 outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) highlighted the risks to human health posed by emerging viral diseases and emphasized the need for specific therapeutic agents instead of relying on existing broadly active antiviral compounds. The development of rapid screening assays is essential for antiviral drug discovery. Thus, a screening system for anti-SARS-CoV agents was developed, which evaluated compound potency, specificity and cytotoxicity at the initial screening phase. Cell lines were engineered to constitutively express an enhanced green fluorescent protein (EGFP) and used to detect (1) antiviral potency in SARS-CoV infection tests; (2) antiviral specificity in tests using the porcine coronavirus transmissible gastroenteritis virus (TGEV); and (3) cytotoxicity in the same assays without virus challenge. The assay system involves minimal manipulation after assay set-up, facilitates automated read-out and minimizes risks associated with hazardous viruses. The suitability of this assay system in drug discovery was demonstrated by screening of 3388 small molecule compounds. The results show that these assays can be applied to high-throughput screening for identification of inhibitors selectively active against SARS-CoV.
DOI: 10.1016/j.jviromet.2005.05.010
PubMed: 15961169
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002684
- to stream PubMed, to step Curation: 002684
- to stream PubMed, to step Checkpoint: 002751
- to stream Ncbi, to step Merge: 001010
- to stream Ncbi, to step Curation: 001010
Links to Exploration step
pubmed:15961169Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.</title><author><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name><affiliation wicri:level="1"><nlm:affiliation>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800</wicri:regionArea><wicri:noRegion>Mechelen 2800</wicri:noRegion></affiliation></author><author><name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name></author><author><name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name></author><author><name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name></author><author><name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name></author><author><name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name></author><author><name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name></author><author><name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name></author><author><name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15961169</idno><idno type="pmid">15961169</idno><idno type="doi">10.1016/j.jviromet.2005.05.010</idno><idno type="wicri:Area/PubMed/Corpus">002684</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002684</idno><idno type="wicri:Area/PubMed/Curation">002684</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002684</idno><idno type="wicri:Area/PubMed/Checkpoint">002751</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002751</idno><idno type="wicri:Area/Ncbi/Merge">001010</idno><idno type="wicri:Area/Ncbi/Curation">001010</idno><idno type="wicri:Area/Ncbi/Checkpoint">001010</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.</title><author><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name><affiliation wicri:level="1"><nlm:affiliation>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800</wicri:regionArea><wicri:noRegion>Mechelen 2800</wicri:noRegion></affiliation></author><author><name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name></author><author><name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name></author><author><name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name></author><author><name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name></author><author><name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name></author><author><name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name></author><author><name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name></author><author><name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name></author></analytic><series><title level="j">Journal of virological methods</title><idno type="ISSN">0166-0934</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (analysis)</term><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (metabolism)</term><term>Antiviral Agents (pharmacology)</term><term>Cell Line</term><term>Drug Evaluation, Preclinical</term><term>Green Fluorescent Proteins</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux ()</term><term>Antiviraux (analyse)</term><term>Antiviraux (métabolisme)</term><term>Antiviraux (pharmacologie)</term><term>Lignée cellulaire</term><term>Protéines à fluorescence verte</term><term>Réplication virale ()</term><term>Virus du SRAS ()</term><term>Virus du SRAS (physiologie)</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Drug Evaluation, Preclinical</term><term>Green Fluorescent Proteins</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Antiviraux</term><term>Lignée cellulaire</term><term>Protéines à fluorescence verte</term><term>Réplication virale</term><term>Virus du SRAS</term><term>Évaluation préclinique de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The severity and global spread of the 2003 outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) highlighted the risks to human health posed by emerging viral diseases and emphasized the need for specific therapeutic agents instead of relying on existing broadly active antiviral compounds. The development of rapid screening assays is essential for antiviral drug discovery. Thus, a screening system for anti-SARS-CoV agents was developed, which evaluated compound potency, specificity and cytotoxicity at the initial screening phase. Cell lines were engineered to constitutively express an enhanced green fluorescent protein (EGFP) and used to detect (1) antiviral potency in SARS-CoV infection tests; (2) antiviral specificity in tests using the porcine coronavirus transmissible gastroenteritis virus (TGEV); and (3) cytotoxicity in the same assays without virus challenge. The assay system involves minimal manipulation after assay set-up, facilitates automated read-out and minimizes risks associated with hazardous viruses. The suitability of this assay system in drug discovery was demonstrated by screening of 3388 small molecule compounds. The results show that these assays can be applied to high-throughput screening for identification of inhibitors selectively active against SARS-CoV.</div></front></TEI><affiliations><list><country><li>Belgique</li></country></list><tree><noCountry><name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name><name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name><name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name><name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name><name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name><name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name><name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name><name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name></noCountry><country name="Belgique"><noRegion><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001010 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001010 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:15961169
|texte= Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:15961169" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |